In Figure 6, the risk score was significantly increased, when the HER2 subtype and luminal B subtype, the later clinical stage, the larger tumor size, and lymph node metastasis were taken into consideration, confirming the excellent consistency between risk score and prognostic outcomes. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.